Due to COVID-19, my practice only saw urgent or emergent patients at risk of going blind for 3 months in early 2020. Once we began to accept patients for routine in-person visits again, we worked to optimize treatment for a COVID-19 world.
The arrival of the first sustained-release implant, Durysta (bimatoprost intracameral implant, Allergan), in early 2020 was a welcome development as my practice adopted a new model of care that sought to minimize in-person doctor-patient interaction as much as practicable.
For decades, glaucoma treatment has been reactive: We test (Read more...)